NeuroSonix is an Israeli medical device company targeting the market of cerebral embolic protection during cardiac surgical and other minimally invasive procedures. NeuroSonix has conceived, developed and patented a technology and medical devices for the prevention of acute cerebral embolism during open-heart cardiac surgery as well as other invasive and minimally-invasive procedures. The company's technology, which is based on ultrasound, aims to enable a non-invasive deflection of embolic material flowing inside the body, away from the cerebral arteries. This new ultrasonic modality aims to reduce the embolic load on the patient's brain. The first product developed by the company is the EmBlocker"ž, intended to provide protection from acute cerebral embolism during cardiac surgical procedures. The Protection Collar, the company's second product, is intended for embolic protection during minimally-invasive procedures and Cath-lab practice.

BioProtect has developed a minimally invasive, biodegradable, biological balloon implant which reduces rectal toxicity in prostate cancer radiation therapy.

MST - Medical Smart Tools was founded in 2004 with the mission to develop image guided surgery technology solutions. The Company aims to improve laparoscopic and other minimally invasive surgical procedures and medical staff effectiveness, thus increasing hospital efficiencies, reducing surgical costs, and improving patient outcomes. MST is working within NGT, a private technological incubator in Nazareth, Israel. MST presents the market with a smart disposable Robotic Arm camera holder for laparoscopy, based on advanced image technology. The system is comprised of a computer-controlled mechanism for mechanical camera motivation, intuitive interface between the surgeon and the mechanical system. The company's R&D efforts are spearheaded by a core group of engineers with expertise in image processing, dynamics of mechanisms, multi-link systems and biomechanics. The Company is backed by strong and experienced management and professional medical advisors.

Coromedic is a privately owned biomedical start up company working to manufacture devices and develop techniques to facilitate coronary artery bypass surgery in a minimally invasive technique. The company's flagship products, the proximal anastomosis device, the distal anastomosis device and the internal mammary artery harvester are a in a set of invaluable tools aimed at easing the complications associated with the conventional surgery. The company have worked to design and build prototypes of the company's products and develop a business strategy, consulting with numerous professionals to assess the feasibility and utility of the company's product and business model. The process of idea protection and patent application is ongoing, a provisional patent for one of the company's products, the proximal anastomosis devices is in place and the application for patent protection of all the company's products is underway. The prototype of the company's first device, the proximal anastomosis device is built and tested in the wet lab. The company are currently working on prototype assembly of the company's second and third products, after which lab animal experiments in the appropriate facilities will take place and then approval for clinical trials and their undertaking will commence.

Endogun Medical Systems Ltd. is a medical device company developing: EndoFast Reliant„ system for Pelvic Organ Prolapse repair.

Axial Biotech, founded in 2002 by a group of spine surgeons and geneticists, is focused on the use of genetics and the development of minimally invasive fusionless devices to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is a company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices. In its initial genetic product development initiative, Axial has made progress towards the discovery of a location in the human genome that is associated with adolescent idiopathic scoliosis. In addition, Axial's founders have developed five motion preserving, fusionless surgical devices (including such device currently being implanted in humans) that have the promise of expanding the current treatable scoliosis patient population by a factor of ten. Axial intends to use its genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery/product development methodology to other spinal diseases. Axial (www.axialbiotech.com) is located in Salt Lake City, Utah.